



2014 eCQM Flow  
Measure Identifier: CMS140v3  
NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR)  
Positive Breast Cancer



\*Please refer to the specific section of the eCQM measure to identify the QDM data elements and associated value sets for use in reporting this eCQM measure.

2014 eCQM Flow  
Measure Identifier: CMS140v3


NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR)  
Positive Breast Cancer



\*Please refer to the specific section of the eCQM measure to identify the QDM data elements and associated value sets for use in reporting this eCQM measure.

2014 eCQM Flow  
Measure Identifier: CMS140v3


NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR)  
Positive Breast Cancer



\*Please refer to the specific section of the eCQM measure to identify the QDM data elements and associated value sets for use in reporting this eCQM measure.

2014 eCQM Flow  
Measure Identifier: CMS140v3

NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR)  
Positive Breast Cancer



\*Please refer to the specific section of the eCQM measure to identify the QDM data elements and associated value sets for use in reporting this eCQM measure.

2014 eCQM Flow  
Measure Identifier: CMS140v3  
NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-III C Estrogen Receptor/Progesterone Receptor (ER/PR)  
Positive Breast Cancer

**SAMPLE CALCULATION:**

**Performance Rate =**

$$\frac{\text{Numerator (a=9 patients)}}{\text{Denominator (b=20 patients) - Denominator Exclusions (N/A) - Denominator Exceptions (c^1+c^2+c^3+c^4+c^5+c^6+c^7+c^8=5 patients)}} = 60.00\%$$

## 2014 eCQM Flows

Measure Identifier: CMS140v3

### NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer

Please refer to the specific section of the eCQM to identify the QDM data elements and associated value sets for use in reporting this eCQM.

1. Start Initial Patient Population
2. Check Patient Characteristic Sex and Patient Characteristic Birthdate:
  - a. If QDM data element, FEMALE, and QDM data element, BIRTH DATE, is greater than or equal to 18 years starts before start of measurement period equals No, do not include in Initial Patient Population. Stop Processing.
  - b. If QDM data element, FEMALE, and QDM data element, BIRTH DATE, greater than or equal to 18 years starts before start of measurement period equals Yes, proceed to check Diagnosis Active.
3. Check Diagnosis Active:
  - a. If First Occurrence A of QDM data element, BREAST CANCER, less than or equal to 5 years starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION during measurement period equals Yes, proceed to check Encounter Performed.
  - b. If First Occurrence A of the QDM data element, BREAST CANCER, less than or equal to 5 years starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, during measurement period equals No, do not include in the Initial Patient Population. Stop Processing.
4. Check Encounter Performed: Total number of encounters must be greater than or equal to 2:
  - a. If greater than or equal to 2 counts of Occurrence A of QDM data element, OFFICE VISIT, or QDM data element, PATIENT PROVIDER INTERACTION, during measurement period equals Yes, include in the Initial Patient Population and proceed to the Denominator.
  - b. If greater than or equal to 2 counts of Occurrence A of the QDM data element, OFFICE VISIT, or QDM data element, PATIENT PROVIDER INTERACTION, during measurement period equals No, do not include in the Initial Patient Population. Stop Processing.
5. Start Denominator
  - a. Denominator equals the Initial Patient Population.
6. Check Diagnosis Active:
  - a. If Occurrence A of QDM data element, BREAST CANCER ER OR PR POSITIVE, starts before or during Occurrence A of Encounter Performed QDM data element OFFICE VISIT or QDM data element FACE-TO-FACE INTERACTION but does not start before start of Occurrence A of QDM data element, BREAST CANCER, equals Yes, proceed to check Procedure Result.
  - b. If Occurrence A of QDM data element, BREAST CANCER ER OR PR POSITIVE, starts before or during Occurrence A of Encounter Performed QDM data element



OFFICE VISIT or QDM data element FACE-TO-FACE INTERACTION but does not start before start of Occurrence A of QDM data element, BREAST CANCER, equals No, do not include in the Denominator Eligible Population. Stop Processing.

7. Check Procedure Result:
  - a. If Occurrence A of QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Distant Metastasis Status M0), starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION but does not start before start of Occurrence A of QDM data element BREAST CANCER, equals Yes, proceed to check Procedure Result.
  - b. If Occurrence A of QDM data element, CLINICAL STAGING PROCEDURE (result: Colon Distant Metastasis Status M0), starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION but does not start before start of Occurrence A of QDM data element BREAST CANCER, equals No, do not include in the Denominator Eligible Population. Stop Processing.
8. Check Procedure Result:
  - a. If Occurrence A of QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Regional Lymph Node Status N3), equals Yes, include in Denominator Eligible Population. Denominator is represented by letter B in the sample calculation listed at the end of this document. Letter B equals 20 patients in the sample calculation.
  - b. If Occurrence A of QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Regional Lymph Node Status N3), equals No, proceed to check next Procedure Result.
9. Check Procedure Result:
  - a. If Occurrence A of QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T0 or T1 or T1a or T1b or T1c or T1mi), AND (result: Breast Cancer Regional Lymph Node Status N1 or pN1a or pN1b or pN1c or pN1mi or N2), equals Yes, include in Denominator Eligible Population. Denominator is represented by letter B in the sample calculation listed at the end of this document. Letter B equals 20 patients in the sample calculation.
  - b. If Occurrence A of QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T0 or T1 or T1a or T1b or T1c or T1mi) AND (result: Breast Cancer Regional Lymph Node Status N1 or pN1a or pN1b or pN1c or pN1mi or N2), equals No, proceed to check next Procedure Result.
10. Check Procedure Result:
  - a. If Occurrence A of QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T2 or T3 or T4) AND (result: Breast Cancer Regional Lymph Node Status N0 or N1 or N2), equals Yes, include in Denominator Eligible Population. Denominator is represented by letter B in the sample calculation listed at the end of this document. Letter B equals 20 patients in the sample calculation.
  - b. If Occurrence A of QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T2 or T3 or T4), AND (result: Breast Cancer Regional Lymph Node Status N0 or N1 or N2), equals No, proceed to check next Procedure Result.

11. Check Procedure Result:
  - a. Occurrence A of QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T1c), AND (result: Breast Cancer Regional Lymph Node Status N0), equals Yes, include in Denominator Eligible Population. Denominator is represented by letter B in the sample calculation listed at the end of this document. Letter B equals 20 patients in the sample calculation.
  - b. Occurrence A of QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T1c), AND (result: Breast Cancer Regional Lymph Node Status N0), equals No, do not include in Denominator Eligible Population. Stop Processing.
12. Start Numerator
13. Check Medication Order:
  - a. If QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals Yes, include in Numerator Count. Numerator is represented by letter A<sup>1</sup> in the sample calculation listed at the end of this document. Letter A<sup>1</sup> equals 3 patients in the sample calculation.
  - b. If QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals No, proceed to check Medication Active.
14. Check Medication Active:
  - a. If Occurrence A of QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, equals Yes, include in Numerator Count. Numerator is represented by letter A<sup>2</sup> in the sample calculation listed at the end of this document. Letter A<sup>2</sup> equals 3 patients in the sample calculation.
  - b. If Occurrence A of QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, equals No, proceed to check Medication Active.
15. Check Medication Active:
  - a. If Occurrence A of QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION, equals Yes, include in Numerator Count. Numerator is represented by letter A<sup>3</sup> in the sample calculation listed at the end of this document. Letter A<sup>3</sup> equals 3 patients in the sample calculation.
  - b. If Occurrence A of QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION, equals No, proceed to Denominator Exceptions.
16. Start Denominator Exceptions
17. Check Diagnosis Active:



- a. If Occurrence A of QDM data element, BREAST CANCER is less than or equal to 120 day(s) starts before or during measurement end date equals Yes, include in Denominator Exception Count. Denominator Exception, which is represented by letter C<sup>1</sup> in the sample calculation listed at the end of this document. Letter C<sup>1</sup> equals 0 patient in the sample calculation.
  - b. If Occurrence A of QDM data element, BREAST CANCER is less than or equal to 120 day(s) starts before or during measurement end date equals No, proceed to check Procedure Performed.
18. Check Procedure Performed:
  - a. If QDM data element, RADIATION THERAPY II, or QDM data element, CHEMOTHERAPY, during measurement period equals Yes, include in Denominator Exception Count. Denominator Exception, which is represented by letter C<sup>2</sup> in the sample calculation listed at the end of this document. Letter C<sup>2</sup> equals 1 patient in the sample calculation.
  - b. If QDM data element, RADIATION THERAPY II, or QDM data element, CHEMOTHERAPY, during measurement period, equals No, proceed to check Procedure Performed.
19. Check Procedure Performed:
  - a. If QDM data element, BILATERAL OOPHORECTOMY starts before or during Occurrence A of Encounter Performed QDM data element OFFICE VISIT or QDM data element FACE-TO-FACE INTERACTION, equals Yes, include in Denominator Exception Count. Denominator Exception which is represented by letter C<sup>3</sup> in the sample calculation listed at the end of this document. Letter C<sup>3</sup> equals 1 patient in the sample calculation.
  - b. If QDM data element, BILATERAL OOPHORECTOMY starts before or during Occurrence A of Encounter Performed QDM data element OFFICE VISIT or QDM data element FACE-TO-FACE INTERACTION, equals No, proceed to check Medication Order Not Done.
20. Check for Medication Order Not Done:
  - a. If QDM data element, MEDICAL REASON, or QDM data element, PATIENT REASON, or QDM data element, SYSTEM REASON, for Tamoxifen or Aromatase Inhibitor Therapy Ingredient Grouping Value Set starts during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals Yes, include in Denominator Exception Count. Denominator Exception, which is represented by letter C<sup>4</sup> in the sample calculation listed at the end of this document. Letter C<sup>4</sup> equals 1 patient in the sample calculation.
  - b. If QDM data element, MEDICAL REASON, or QDM data element, PATIENT REASON, or QDM data element, SYSTEM REASON, for Tamoxifen or Aromatase Inhibitor Therapy Ingredient Grouping Value Set starts during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals No, proceed to check Medication Intolerance or Medication Allergy.
21. Check Medication Intolerance or Medication Allergy:
  - a. If QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY or QDM data element TAMOXIFEN or AROMATASE INHIBITOR THERAPY INGREDIENT, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element,

FACE-TO-FACE INTERACTION, equals Yes include in Denominator Exception Count. Denominator Exception which is represented by letter C<sup>5</sup> in the sample calculation listed at the end of this document. Letter C<sup>5</sup> equals 0 patients in the sample calculation.

- b. If QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, or QDM data element TAMOXIFEN or AROMATASE INHIBITOR THERAPY INGREDIENT, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals No, proceed to check Diagnosis Active.
22. Check Diagnosis Active:
- a. If Occurrence A of QDM data element, INTOLERANCE TO TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, or METASTATIC SITES COMMON TO BREAST CANCER, or QDM data element, ALLERGY TO TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals Yes include in Denominator Exception Count. Denominator Exception which is represented by letter C<sup>6</sup> in the sample calculation listed at the end of this document. Letter C<sup>6</sup> equals 0 patients in the sample calculation.
  - b. If Occurrence A of QDM data element, INTOLERANCE TO TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, or METASTATIC SITES COMMON TO BREAST CANCER, or QDM data element, ALLERGY TO TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals No, proceed to check Medication Active.
23. Check Medication Active:
- a. If Occurrence A of QDM data element, GONADOTROPIN-RELEASING HORMONE ANALOGUE MEDICATION, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals Yes, include in Denominator Exception Count. Denominator Exception which is represented by letter C<sup>7</sup> in the sample calculation listed at the end of this document. Letter C<sup>7</sup> equals 1 patient in the sample calculation.
  - b. If Occurrence A of QDM data element, GONADOTROPIN-RELEASING HORMONE ANALOGUE MEDICATION, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals No, proceed to check Patient Characteristic Clinical Trial Participant.
24. Check Patient Characteristic Clinical Trial Participant:
- a. If Occurrence A of QDM data element, CLINICAL TRIAL PARTICIPANT, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals Yes include in Denominator Exception Count. Denominator Exception which is represented by letter C<sup>8</sup> in the sample calculation listed at the end of this document. Letter C<sup>8</sup> equals 1 patient in the sample calculation.

- b. If Occurrence A of QDM data element, CLINICAL TRIAL PARTICIPANT, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or QDM data element, FACE-TO-FACE INTERACTION, equals No, include in the No/Missing Data Submitted Count. Stop processing.

**SAMPLE CALCULATION:**

**Performance Rate =**

Numerator (a = 9 patients)

÷

Denominator (b=20 patients) – *Denominator Exclusions (N/A)* – Denominator Exceptions ( $c^1+c^2+c^3+c^4+c^5+c^6+c^7+c^8= 5$  patients)  
= 60.00%